Medscape1d
Promise for CAR T-Cell Therapies in Solid Tumors?
CAR T-cell therapies have demonstrated efficacy in treating blood cancers but, so far, their safety and effectiveness in ...
Tempest Granted Fast Track Designation from the U.S. Food and Drug Administration for Amezalpat to Treat Patients with Hepatocellular Carcinoma
Fast Track Designation highlights potential of amezalpat to address unmet need for patients with HCCAmezalpat builds momentum with both ...
Medical Dialogues3d
Hepatocellular Carcinoma After Hepatitis C Cure: Study Emphasizes The Need for Long-Term Surveillance
China: A recent study published in the Annals of Hepatology has emphasized the influence of age on hepatocellular carcinoma ...
BMY Gets Positive CHMP Opinion for Opdivo, Yervoy Combo and Breyanzi
The CHMP recommends approval of Bristol Myers' Opdivo plus Yervoy for the first-line treatment of hepatocellular carcinoma ...
Bristol Myers gets positive CHMP opinion for Opdivo plus Yervoy
Squibb announced that the Committee for Medicinal Products for Human Use of the European Medicines Agency has recommended ...
Bristol Myers Gets CHMP Backing for Expanded Breyanzi, Opdivo/Yervoy Uses
Bristol Myers on Friday said the European Medicines Agency's Committee for Medicinal Products for Human Use recommended approval of Breyanzi for the treatment of adults with relapsed or refractory ...
CHANCE 2005/CARES-005 Study Shows PFS Benefit with Combination of Camrelizumab/Rivoceranib and TACE in Unresectable hepatocellular carcinoma (HCC)
Results of CHANCE 2005/CARES-005 study were unveiled by Dr Gao-Jun Teng from Zhongda Hospital, Southeast University, China, ...